BR112015006370A8 - composto citotóxico, sua mistura e sal farmaceuticamente aceitável, sal/solvente complexo, metal complexo, exceto um com qualquer de fe2+, fer+, co2+, complexo solvente ou pró-fármico, bem como seu uso e composição o compreendendo - Google Patents
composto citotóxico, sua mistura e sal farmaceuticamente aceitável, sal/solvente complexo, metal complexo, exceto um com qualquer de fe2+, fer+, co2+, complexo solvente ou pró-fármico, bem como seu uso e composição o compreendendo Download PDFInfo
- Publication number
- BR112015006370A8 BR112015006370A8 BR112015006370A BR112015006370A BR112015006370A8 BR 112015006370 A8 BR112015006370 A8 BR 112015006370A8 BR 112015006370 A BR112015006370 A BR 112015006370A BR 112015006370 A BR112015006370 A BR 112015006370A BR 112015006370 A8 BR112015006370 A8 BR 112015006370A8
- Authority
- BR
- Brazil
- Prior art keywords
- complex
- solvent
- salt
- fer
- pro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
resumo meios e métodos para tratamento de tumores sólidos em um composto citotóxico de fórmula geral (i) r é h ou metila ou metileno substituído por alquila linear ou ramificada c1-c4, r1 é selecionado a partir do grupo que consiste em h, alquila linear ou ramificada c1-c4, metóxi, metóxi substituído por a partir de um a três grupos flúor, halogênio; r2 é h ou alquila linear ou ramificada c1-c4; x é ch ou n; y é ch ou n.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1200571 | 2012-09-21 | ||
| SE1200571-6 | 2012-09-21 | ||
| PCT/SE2013/000142 WO2014046589A1 (en) | 2012-09-21 | 2013-09-17 | Means and method for treating solid tumours |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112015006370A2 BR112015006370A2 (pt) | 2017-07-04 |
| BR112015006370A8 true BR112015006370A8 (pt) | 2019-10-08 |
| BR112015006370B1 BR112015006370B1 (pt) | 2022-04-12 |
Family
ID=50342515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015006370-5A BR112015006370B1 (pt) | 2012-09-21 | 2013-09-17 | Composto citotóxico, sal farmaceuticamente aceitável do mesmo, mistura, composição farmacêutica e uso do referido composto |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9562046B2 (pt) |
| EP (1) | EP2900667B1 (pt) |
| JP (1) | JP6258332B2 (pt) |
| KR (1) | KR102190768B1 (pt) |
| CN (1) | CN104662022A (pt) |
| AU (1) | AU2013318672B2 (pt) |
| BR (1) | BR112015006370B1 (pt) |
| CA (1) | CA2884832C (pt) |
| DK (1) | DK2900667T3 (pt) |
| EA (1) | EA026465B1 (pt) |
| ES (1) | ES2734479T3 (pt) |
| HK (1) | HK1206352A1 (pt) |
| HU (1) | HUE044767T2 (pt) |
| IL (1) | IL237569B (pt) |
| MX (1) | MX369470B (pt) |
| PL (1) | PL2900667T3 (pt) |
| PT (1) | PT2900667T (pt) |
| SG (1) | SG11201502209PA (pt) |
| WO (1) | WO2014046589A1 (pt) |
| ZA (1) | ZA201501558B (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201605083SA (en) | 2011-03-21 | 2016-08-30 | Vivolux Ab | Treatment of solid tumours |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| CA3008084A1 (en) | 2015-12-18 | 2017-06-22 | Vivolux Ab | Pharmaceutical composition comprising indole derivatives, process for preparation and use thereof |
| CN106831776B (zh) * | 2017-03-16 | 2018-12-07 | 河北科技大学 | 5,10-二氢吡啶并吡嗪并三嗪类化合物及其应用 |
| WO2019101897A1 (en) * | 2017-11-23 | 2019-05-31 | Deutsches Krebsforschungszentrum | Iron chelators in tumor therapy |
| CN110964018B (zh) * | 2019-12-03 | 2022-03-11 | 华侨大学 | 一种吲哚类衍生物及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0233101A1 (fr) | 1986-01-13 | 1987-08-19 | Ire-Celltarg S.A. | Dérivés de vinblastine et composition pharmaceutique les contenant |
| US5480906A (en) | 1994-07-01 | 1996-01-02 | Eli Lilly And Company | Stereochemical Wortmannin derivatives |
| IL121272A (en) | 1997-07-10 | 2000-06-01 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia |
| US6660737B2 (en) | 2001-05-04 | 2003-12-09 | The Procter & Gamble Company | Medicinal uses of hydrazones |
| GB0300804D0 (en) * | 2003-01-14 | 2003-02-12 | Novo Pharmaceuticals De Ltd | Compounds and their use |
| US8076352B2 (en) * | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| US7767689B2 (en) * | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
| ITMI20040874A1 (it) * | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | Derivati indolici ed azaindolici con azione antitumorale |
| JP2008520669A (ja) | 2004-11-19 | 2008-06-19 | シバ バイオメディカル，エルエルシー | エリスロポエチン抵抗性を治療する方法 |
| MX2008014292A (es) | 2006-05-09 | 2008-11-18 | Novartis Ag | Combinacion que comprende un quelante de hierro y un agente anti-neoplastico, y uso de la misma. |
| WO2009035534A2 (en) * | 2007-09-07 | 2009-03-19 | The Cleveland Clinic Foundation | Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) |
| KR101208587B1 (ko) | 2009-06-24 | 2012-12-06 | 여오영 | 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물 |
| SG10201605083SA (en) * | 2011-03-21 | 2016-08-30 | Vivolux Ab | Treatment of solid tumours |
-
2013
- 2013-09-17 HU HUE13839817 patent/HUE044767T2/hu unknown
- 2013-09-17 PL PL13839817T patent/PL2900667T3/pl unknown
- 2013-09-17 CN CN201380049080.3A patent/CN104662022A/zh active Pending
- 2013-09-17 SG SG11201502209PA patent/SG11201502209PA/en unknown
- 2013-09-17 WO PCT/SE2013/000142 patent/WO2014046589A1/en active Application Filing
- 2013-09-17 EP EP13839817.7A patent/EP2900667B1/en active Active
- 2013-09-17 PT PT13839817T patent/PT2900667T/pt unknown
- 2013-09-17 KR KR1020157010109A patent/KR102190768B1/ko active IP Right Grant
- 2013-09-17 US US14/435,707 patent/US9562046B2/en active Active
- 2013-09-17 JP JP2015533011A patent/JP6258332B2/ja active Active
- 2013-09-17 CA CA2884832A patent/CA2884832C/en active Active
- 2013-09-17 EA EA201590315A patent/EA026465B1/ru not_active IP Right Cessation
- 2013-09-17 ES ES13839817T patent/ES2734479T3/es active Active
- 2013-09-17 DK DK13839817.7T patent/DK2900667T3/da active
- 2013-09-17 MX MX2015003607A patent/MX369470B/es active IP Right Grant
- 2013-09-17 BR BR112015006370-5A patent/BR112015006370B1/pt active IP Right Grant
- 2013-09-17 AU AU2013318672A patent/AU2013318672B2/en active Active
-
2015
- 2015-03-04 IL IL237569A patent/IL237569B/en active IP Right Grant
- 2015-03-06 ZA ZA2015/01558A patent/ZA201501558B/en unknown
- 2015-07-22 HK HK15107010.4A patent/HK1206352A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2900667B1 (en) | 2019-06-05 |
| AU2013318672A1 (en) | 2015-03-19 |
| HUE044767T2 (hu) | 2019-11-28 |
| CN104662022A (zh) | 2015-05-27 |
| ZA201501558B (en) | 2016-01-27 |
| US9562046B2 (en) | 2017-02-07 |
| ES2734479T3 (es) | 2019-12-10 |
| EA201590315A1 (ru) | 2015-08-31 |
| DK2900667T3 (da) | 2019-08-26 |
| CA2884832C (en) | 2020-09-15 |
| JP6258332B2 (ja) | 2018-01-10 |
| MX369470B (es) | 2019-11-08 |
| IL237569A0 (en) | 2015-04-30 |
| PT2900667T (pt) | 2019-09-04 |
| JP2015529244A (ja) | 2015-10-05 |
| CA2884832A1 (en) | 2014-03-27 |
| BR112015006370B1 (pt) | 2022-04-12 |
| EP2900667A4 (en) | 2016-06-15 |
| WO2014046589A1 (en) | 2014-03-27 |
| EA026465B1 (ru) | 2017-04-28 |
| EP2900667A1 (en) | 2015-08-05 |
| AU2013318672B2 (en) | 2017-09-28 |
| HK1206352A1 (en) | 2016-01-08 |
| US20150259349A1 (en) | 2015-09-17 |
| KR102190768B1 (ko) | 2020-12-14 |
| BR112015006370A2 (pt) | 2017-07-04 |
| KR20150058441A (ko) | 2015-05-28 |
| PL2900667T3 (pl) | 2019-11-29 |
| MX2015003607A (es) | 2015-06-05 |
| SG11201502209PA (en) | 2015-05-28 |
| IL237569B (en) | 2020-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20130543A (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| BR112015006370A8 (pt) | composto citotóxico, sua mistura e sal farmaceuticamente aceitável, sal/solvente complexo, metal complexo, exceto um com qualquer de fe2+, fer+, co2+, complexo solvente ou pró-fármico, bem como seu uso e composição o compreendendo | |
| NI201500054A (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| DOP2016000140A (es) | Inhibidores de syk | |
| CO6620055A2 (es) | Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| CR20160099A (es) | Formulación de inhibidores de la syk | |
| CU24272B1 (es) | Derivados de tetrahidropirido-pirimidina como inhibidores de mek | |
| EA201390766A1 (ru) | БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ | |
| BR112013031405A2 (pt) | piridopirazinas substituídas como novos inibidores de syk | |
| BR112016010080A8 (pt) | compostos de pirazolopirimidina, composição farmacêutica e seu uso | |
| PE20181519A1 (es) | Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido | |
| BR112012026767A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal | |
| BR112013002375A2 (pt) | composto, composição farmacêutica, métodos de tratar um indivíduo para um distúrbio proliferativo de induzir a apoptose das células cancerígenas, e de inibir a atividade de cinase em um mamífero, e, processo de preparação de composto | |
| GT201300137A (es) | Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak | |
| CR20140275A (es) | Triazolopiridinas sustituidas | |
| UY33337A (es) | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS | |
| ECSP11011258A (es) | Pirimidinas fusionadas | |
| EA201591545A1 (ru) | C-3 алкил- и алкенил-модифицированные производные бетулиновой кислоты | |
| DOP2014000036A (es) | Compuestos de piridazinona y su uso como inhibidores daao | |
| UY32153A (es) | Inhibidores de piridomidinona de pi13ka(alfa) y mtor | |
| AR097543A1 (es) | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO | |
| CR20140217A (es) | Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas ii | |
| AR097545A1 (es) | COMPUESTOS A BASE DE PIRAZOLO[1,5-a]PIRIMIDINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO | |
| AR086647A1 (es) | Metodos para tratar el mesotelioma con un compuesto inhibidor de la pi3k |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/09/2013, OBSERVADAS AS CONDICOES LEGAIS. |